Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eli Lilly: Cymabalta reduces pain severity of knee osteoarthritis

Eli Lilly: Cymabalta reduces pain severity of knee osteoarthritis

16th June 2008

Eli Lilly has announced the publication of new data suggesting that patients with osteoarthritis of the knee treated with Cymbalta (duloxetine HCl) experienced sign reductions in pain.

The company presented these results to the annual congress of the European League Against Rheumatism last week in Paris.

According to the study data, patients treated with 60mg and 120mg of the compound showed significant pain improvement compared to placebo from the first week of treatment, with this improvement maintained throughout the 13-week trial.

Enhanced patient outcomes were also observed using the Patient Global Impressions of Improvement measure and the Western Ontario and McMaster Universities physical functioning subscale.

Amy Chappell, a medical fellow at Eli Lilly, said: “Although the exact mechanism of action is unknown, this study may provide important insights into the treatment of pain in the central nervous system.”

She added that the data from the trials are important because it marks the first time the compound has been studies in a large placebo-controlled trial in an inflammatory disease state.

Last week, Eli Lilly announced that it had signed an agreement with TransPharma Medical relating to the licensing and development of ViaDerm-hPTH (1-34) as a treatment for osteporosis.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.